Drug assessment at a glance

Do you have questions about a drug, but not a lot of time? Or would you like to show the results of our independent assessment simply and concisely in a presentation – for example, as part of a continuing medical education session? Then take a look at our ‘Drug assessment at a glance’ format, where you can find the key information and results from our dossier assessments in slide format – as a short, clear summary.

Background: In the AMNOG procedure IQWiG assesses, on behalf of the Federal Joint Committee ( GBA), whether a newly authorised drug has a patient-relevant added benefit in comparison with the appropriate comparator therapy. This assessment is based on the dossier submitted by the pharmaceutical company to the GBA following marketing authorisation. On the basis of this ‘dossier assessment’, the GBA then adopts a resolution on the extent of the added benefit. The GBA’s resolution then forms the basis for reimbursement price negotiations between the drug manufacturer and the National Association of Statutory Health Insurance Funds.